Inclusion Criteria:  1. Men or women, age ≥18. 2.Subjects with advanced malignancy histopathologically and/or cytologically, with at least one evaluable tumor lesion. 3.ECOG PS is 0 or 1. 4.Survival expectation of at least 3 months. 5.Adequate organs and hematopoietic functions 6.Voluntarily signing of informed consent  Exclusion Criteria:  1.Subjects with brain metastases of clinically active central nervous system (CNS). 2.Subjects that require to take anticoagulants and/or aspirin. 3.Blood transfusion within 2 weeks prior to the first administration of study treatment. 4.Inadequately controlled body cavity effusions. 5.Subjects with active, or have a history and possible recurrence of autoimmune diseases . 6.Have uncontrolled systemic diseases. 7.Subjects who had received anticancer therapy or radiotherapy within 4 weeks or 5 half-lives (whichever is shorter) before enrollment. 8.Subjects are known to have previously experienced severe allergic reactions to large molecular protein formulations/monoclonal antibodies. 9.Pregnant or lactating women.